Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Nearing Finish Line, HCV Race Focuses On Salvage Therapy

Nov 24 2016

• By Joseph Haas

Related Content

Gilead Sees Prospects For Declining HCV Revenues To Stabilize

Jul 28 2016

Another Strong Quarter For AbbVie, But How Long Will Good Times Last?

Jul 30 2016

Merck Hep C Drug Zepatier OK'd

Jan 29 2016

Tackling Tough-To-Treat Patients As HCV Cure Rates Near 100%

Apr 22 2016

Combination Strategies A Common Thread In NASH R&D

Nov 21 2016

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Nov 02 2016

Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy

Jun 28 2016

Related Companies

Gilead Sciences, Inc.

Merck & Co., Inc.

AbbVie Inc.

Johnson & Johnson

Idenix Pharmaceuticals, Inc.

Additional Topics

Business Strategies Clinical Trials Commercial Post Market Regulation & Studies Research & Development Infectious Diseases Liver & Hepatic Pipeline Watch BioPharmaceutical

More from Anti-infective

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window